AIM
NKTR icon

Aigen Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Aigen Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-804
Closed -$146K – 903
2021
Q4 		$146K Buy
+804
New +$174K 0.01% 967
2020
Q4 		– Sell
-1,414
Closed -$352K – 956
2020
Q3 		$352K Sell
1,414
-3,816
-73% -$1.2M 0.04% 493
2020
Q2 		$1.82M Buy
5,230
+4,990
+2,079% +$1.56M 0.23% 116
2020
Q1 		$64K Buy
+240
New +$74.2K 0.01% 940

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Aigen Investment Management's NKTR Position: Q1 2022 in Review

Aigen Investment Management sold out of Nektar Therapeutics (NKTR) in Q1 2022, closing a stake of 804 shares — an estimated $146K sold.

Aigen Investment Management first reported a position in NKTR in Q1 2020 and held it in 4 quarters. The position peaked at $1.82M in Q2 2020. 239 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

  • Aigen Investment Management reported no remaining Nektar Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Aigen Investment Management sold 804 Nektar Therapeutics shares in Q1 2022, an estimated $146K.
  • Aigen Investment Management first reported a position in Nektar Therapeutics in Q1 2020 and held it in 4 quarters.
  • Aigen Investment Management's Nektar Therapeutics position peaked at $1.82M in Q2 2020.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on Aigen Investment Management's 13F filing for Q1 2022, filed 5 May 2022.